ClinicalTrials.gg
Active, not recruitingNCT05645172RETAINUpdated Oct 16, 2026

Retention Rate of Acalabrutinib in a Non-interventional Setting

An observational study in Chronic Lymphocytic Leukaemia (CLL), sponsored by AstraZeneca. Active, not recruiting at 61 sites in Germany. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by AstraZeneca · Observational

How we know

Updated Oct 16, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
193
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Leukemia, B-Cell with a site in Germany — 7 open to participants now, 11 under way, 3 of them phase 3. Leukemia, B-Cell · Germany.

Started
2022
with 1 other
Observational
4 of 21
2 open now
Primary completion
2027-04
later than 2 of 10 live
Registered
16th of 21
by date
Lead sponsor
3 of 21
AstraZeneca

Among the 21 studies in Leukemia, B-Cell with a site in Germany, this one is one of 2 that started in 2022, is one of 4 observational ones, reaches primary completion later than 2 of the 10 other live ones, and was the 16th registered.

Leukemia, B-Cell

191 studies on the registry are indexed under Leukemia, B-Cell; 53 are open to participants now.

Browse Leukemia, B-Cell studies →

Open to participants now

7 of the 21 studies in Leukemia, B-Cell with a site in Germany are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 40 Leukemia, B-Cell studies recruiting now, 19 (48%) set no upper age limit and 16 (40%) stop at 75 or younger; 16 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Leukemia, B-Cell with a site in Germany, or all of them as a file.
02

Study summary

Retention rate of acalabrutinib in a non-interventional setting. This is a prospective, multicentre, non-interventional study to collect real-world data on retention rates of CLL patients prescribed with acalabrutinib in Germany.

Read the detailed description

This observational study will prospectively assess acalabrutinib therapy retention of CLL patients one year and 2 years after treatment initiation with acalabrutinib in routine clinical practice. Furthermore, therapy adherence, treatment efficacy, overall survival, and QoL to analyse the possible influence of psychological aspects of the patient-based disease perception, a four-group-segmentation for acceptance and perceived control of the health state will be conducted. Finally, disease-, treatment-, and patient-specific factors possibly affecting therapy retention will be analysed: sociodemographic factors, disease and treatment characteristics, comorbidities, therapy adherence, treatment effectiveness, safety, QoL, and psychological segmentation.

03

Conditions studied

  • Chronic Lymphocytic Leukaemia (CLL)

Browse trials for

Keywords

  • Acalabrutinib
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

CLL patients with a newly initiated acalabrutinib treatment in routine clinical practice are planned to be included from approximately 75 sites in Germany over a recruitment period of 16 months.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Diagnosis of CLL
  • Ability to understand the study concept and to regularly complete patient questionnaires from physical, mental, and linguistic perspectives
  • Decision to start therapy with acalabrutinib according to the current SmPC. For previously untreated patients as continuous therapy with or without obinutuzumab. OR For patients with at least one prior CLL therapy as continuous monotherapy.
  • Provision of signed form

Exclusion criteria

Exclusion Criteria:

  • Current or planned participation in an interventional clinical trial
  • to treatment with acalabrutinib according to the current SmPC
  • Pregnancy or breast feeding
  • Disease progression on prior BTKi therapy
  • Start of acalabrutinib therapy more than 28 days prior to enrolment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
193 participants (actual)
Patient registry
No

Groups and cohorts

  • Cohort 1

    adult CLL patients (≥ 18 years of age) newly prescribed with acalabrutinib according to clinical routine will be included independent of the patient age, disease stage, existence of genetic risk factors, comorbidities, therapy line, and of the application as combination therapy with obinutuzumab or as monotherapy.

06

What researchers measure

Primary outcomes

  1. Retention rate of CLL

    The primary outcome of this study is the retention rate of CLL patients receiving acalabrutinib in clinical practice after 1 year (= ratio of the number of patients still being prescribed acalabrutinib after 1 year to the number of patients at risk). Cases of death, ongoing treatment interruption, and lost to follow-up will be counted as patients not still being prescribed with acalabrutinib.

    Time frame: 1 year

Secondary outcomes

  1. Retention rate of CLL

    The secondary outcome is the retention rate of CLL patients receiving acalabrutinib in clinical practice after 2 years.

    Time frame: 2 years

  2. General treatment adherence

    General treatment adherence will be assessed over the whole observational period by the self-reported, 8-item structured MMAS-8 questionnaire.

    Time frame: assessed at baseline and 6, 12, and 24 months after start of acalabrutinib treatment

  3. reasons for and duration of therapy interruptions

    Based on acalabrutinib treatment details, the reasons for and duration of therapy interruptions will be calculated and analysed.

    Time frame: time from first prescription until therapy interruptions; assessed up to 40 months

  4. TTD

    Based on acalabrutinib treatment details, the TTD, defined as the time from first prescription until the date of last intake or death, whichever occurs first, will be calculated and the reasons for therapy discontinuation will be analysed.

    Time frame: time from start of acalabrutinib treatment until the date of final discontinuation or death; assessed up to 40 months.

  5. TTNT

    Based on acalabrutinib treatment details, the TTNT, defined as the time of first prescription until start date of the next CLL treatment will be calculated and the reasons for switch of treatment will be analysed. Cases of death will be censored and not considered as TTNT-relevant event.

    Time frame: time from start of acalabrutinib treatment until start of a subsequent CLL treatment; assessed up to 40 months.

  6. TTNT-D

    Based on acalabrutinib treatment details, the TTNT-D, defined as the time of first prescription until start date of the next CLL treatment or death, whichever occurs first, will be calculated.

    Time frame: time from start of acalabrutinib treatment until start of a subsequent CLL treatment or death; assessed up to 40 months

  7. Treatment efficacy and PFS

    Treatment efficacy will be analysed by means of the overall treatment response (CR, PR, PRL, judged by the treating physician and recommended to be in accordance with the guidelines of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL), modified for persistent lymphocytosis, the time to and duration of response, the percentage of patients without treatment response (SD, PD), as well as the time of PFS, defined as the time of first prescription until progression of the disease or death by any cause, whichever occurs first.

    Time frame: time from start of acalabrutinib treatment until disease progression or death by any cause, whichever occurs first; assessed up to 40 months.

  8. Overall survival

    Overall survival will be calculated as the time from first prescription until death by any cause.

    Time frame: time from start of acalabrutinib treatment until death by any cause; assessed up to 40 months.

  9. Patient- and disease-specific factors possibly affecting the retention rate

    Patient- and disease-specific factors possibly affecting the retention rate will be analysed for associations with the following variables: \- Treatment effectiveness (treatment response, PFS)

    Time frame: up to 40 months

  10. Healths-related Quality of Life (HRQoL)-QLQ-C30

    The QoL, as measured by the self-reported QLQ-C30 questionnaires, will be assessed at baseline and every quarterly regular follow-up visit thereafter until end of observation. The time course of the QoL will be visualised and the mean difference from baseline until 6, 12, and 24 months after start of therapy will be calculated. Clinical significance will be defined as minimal important differences (MIDs) of at least 10 points (in either direction) for total scores or subscales of the QLQ-C30.

    Time frame: Patient questionnaires will becollected at time points synchronised with regular visits during study, assessed up to 40 months

  11. Healths-related Quality of Life (HRQoL)-EQ-5D-5L

    The QoL, as measured by the self-reported EQ-5D-5L questionnaires, will be assessed at baseline and every quarterly regular follow-up visit thereafter until end of observation. The time course of the QoL will be visualised and the mean difference from baseline until 6, 12, and 24 months after start of therapy will be calculated.

    Time frame: Patient questionnaires will becollected at time points synchronised with regular visits during study, assessed up to 40 months

  12. Patient- and disease-specific factors possibly affecting the retention rate

    Patient- and disease-specific factors possibly affecting the retention rate will be analysed for associations with the following variables: \- Patient- and disease-specific characteristics (sociodemographic data, disease characteristics and severity, comorbidities (CIRS), comedication).

    Time frame: up to 40 months

  13. Patient- and disease-specific factors possibly affecting the retention rate

    Patient- and disease-specific factors possibly affecting the retention rate will be analysed for associations with the following variables: \- Treatment adherence (MMAS-8).

    Time frame: up to 40 months

  14. Patient- and disease-specific factors possibly affecting the retention rate (Psychological patient segmentation)

    Psychological patient segmentation as determinant for the disease acceptance and disease control will be performed during the baseline visit by using a questionnaire published by Bloem et al. in 2020

    Time frame: at Baseline

  15. Patient- and disease-specific factors possibly affecting the retention rate

    Patient- and disease-specific factors possibly affecting the retention rate will be analysed for associations with the following variables: \- Safety (rate, severity, and duration of SAEs and ADRs)

    Time frame: up to 40 months

07

Study locations

61 sites
  • Research Site
    D Ren, Germany 52353, Germany
  • Research Site
    Herrsching am Ammersee, Germany 82211, Germany
  • Research Site
    L Rrach, Germany 79539, Germany
  • Research Site
    M Nchen, Germany 80804, Germany
  • Research Site
    M Nchen, Germany 81377, Germany
  • Research Site
    N Rnberg, Germany 90449, Germany
  • Research Site
    Neustadt Am R Benberge, Germany 31535, Germany
  • Research Site
    Saarbr Cken, Germany 66113, Germany
  • Research Site
    Sindelfinden, Germany 71065, Germany
  • Research Site
    W Rselen, Germany 52146, Germany
  • Research Site
    Amberg, 92224, Germany
  • Research Site
    Aschaffenburg, 63739, Germany
  • Research Site
    Augsburg, 86150, Germany
  • Research Site
    Bad Homburg, 61352, Germany
  • Research Site
    Bad Liebenwerda, 04924, Germany
  • Research Site
    Bautzen, 02625, Germany
  • Research Site
    Berlin, 10117, Germany
  • Research Site
    Berlin, 13055, Germany
  • Research Site
    Berlin, 13156, Germany
  • Research Site
    Bonn, 53115, Germany
  • Research Site
    Dachau, 85221, Germany
  • Research Site
    Delitzsch, 04509, Germany
  • Research Site
    Dessau, 06487, Germany
  • Research Site
    Dortmund, 44263, Germany
  • Research Site
    Erfurt, 99084, Germany
  • Research Site
    Erfurt, 99085, Germany
  • Research Site
    Essen, 45136, Germany
  • Research Site
    Frankfurt am Main, 60596, Germany
  • Research Site
    Frankfurt am Main, 65929, Germany
  • Research Site
    Garbsen, 30823, Germany
  • Research Site
    Halle, 06110, Germany
  • Research Site
    Hanover, 30161, Germany
  • Research Site
    Hanover, 30625, Germany
  • Research Site
    Heide, 25746, Germany
  • Research Site
    Herten, 45699, Germany
  • Research Site
    Hof, 04509, Germany
  • Research Site
    Kulmbach, 95326, Germany
  • Research Site
    Laatzen, 30880, Germany
  • Research Site
    Landshut, 72764, Germany
  • Research Site
    Lebach, 66822, Germany
  • Research Site
    Leipzig, 04103, Germany
  • Research Site
    Leipzig, 04289, Germany
  • Research Site
    Moers, 47441, Germany
  • Research Site
    Naunhof, 04683, Germany
  • Research Site
    Oldenburg, 26121, Germany
  • Research Site
    Paderborn, 33098, Germany
  • Research Site
    Pasing, 81281, Germany
  • Research Site
    Pirna, 01796, Germany
  • Research Site
    Porta Westfalica, 32457, Germany
  • Research Site
    Potsdam, 14482, Germany
  • Research Site
    Remscheid, 42859, Germany
  • Research Site
    Reutlingen, 72764, Germany
  • Research Site
    Riesa, 01589, Germany
  • Research Site
    Saalfeld, 07318, Germany
  • Research Site
    Schkeuditz, 04435, Germany
  • Research Site
    Schorndorf, 73614, Germany
  • Research Site
    Siegburg, 53721, Germany
  • Research Site
    Straubing, 94315, Germany
  • Research Site
    Twistringen, 27239, Germany
  • Research Site
    Weiden, 92637, Germany
  • Research Site
    Zittau, '02763, Germany
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Dec 2022 (actual). Primary completion is estimated for Apr 2027, 52 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Oct 2026 → Apr 2027 and completion Oct 2026 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2022
First posted
Dec 9, 2022
StartActual
Dec 12, 2022
Primary completionEst.
Apr 15, 2027was Oct 2026
CompletionEst.
Apr 15, 2027was Oct 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 15, 2026→Apr 15, 2027
Oct 16, 2026
Study completion
Oct 15, 2026→Apr 15, 2027
Oct 16, 2026
Enrollment
137→193
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Primary completion Oct 15, 2026→Apr 15, 2027
    Study completion Oct 15, 2026→Apr 15, 2027
    Enrollment 137→193
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05645172
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Dec 9, 2022
Start date
Dec 12, 2022
Primary completion
Apr 15, 2027 (estimated)
Completion
Apr 15, 2027 (estimated)
Last update
Oct 16, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion